Altimmune (ALT) Reports 48-Week MASH Trial Benefits Across Liver Measures

Altimmune reported advancing its Pemvidutide programs, with MASH Phase 3 on track, positive AUD Phase 2 data, and ALD enrollment complete. The company had $480 million in cash and investments, but a Q3 net loss of $31.6 million.

Altimmune, Inc. (ALT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Altimmune Announces Third Quarter 2026 Financial Results and Business Update ​ Global PERFORMA Phase 3 trial in MASH progressing as planned Positive RECLAIM Phase 2 data in AUD highlighted in a late-breaking oral presentation at AASLD The Liver Meeting® 2026 End-of-P

Altimmune reported $480M in cash and investments as of September 30, 2026. The company plans an FDA meeting in December 2026 for its AUD program. This follows the start of a Phase 3 trial and positive Phase 2 results.

Altimmune Inc. (ALT) published 48-week results from its IMPACT Phase 2b trial of pemvidutide for metabolic dysfunction-associated steatohepatitis in The Lancet. The study showed reductions in liver fat, inflammation, and fibrosis, along with weight loss, compared to placebo. The 1.8 mg dose maintained weight loss and glycemic control. Adverse events were mostly mild to moderate. Pemvidutide has FDA Fast Track and Breakthrough Therapy designations for MASH.

Altimmune reported that its phase 2 trial of pemvidutide for alcohol use disorder met the primary endpoint. The company's stock is traded as ALT.

Altimmune reported that pemvidutide showed improvements in heavy drinking days and other clinical measures in the RECLAIM Phase 2 AUD study. The company plans an FDA End-of-Phase 2 meeting in December to discuss Phase 3 program design. Pemvidutide is also in late-stage development for MASH, with Phase 3 PERFORMA initiated in July 2026.